Table 6.

Disease-free survival of breast cancer patients by SULT1E1 genotype and diplotypes

No. patientsPerson-timeRecurrence/deathAdjusted hazards ratio (95% CI)
Genotypes
IVS1-447C>A
CC3065,400.3171.0 (reference)
CA + AA2204,263.3100.7 (0.30-1.50)
IVS4-1653 T>C
TT4578,485.2191.0 (reference)
TC + CC701,251.783.2 (1.39-7.48)
*959G>A
GG2955,521.1141.0 (reference)
GA+AA2334,281.3131.3 (0.58-2.72)
Haplotypes*
CTG-CTG1212,140.841.0 (reference)
CTG-CTA1072,052.851.2 (0.29-4.99)
CTG-CCA39703.664.2 (1.15-15.15)
CTG-ATG1372,702.380.9 (0.22-3.33)
CTA-CTA22229.217.9 (0.77-81.87)
CTA-CCA8132.80
CTA-ATG41826.10
CCA-CCA345.70
CCA-ATG8148.012.1 (0.21-19.84)
ATG-ATG26474.511.6 (0.17-14.35)
Others13197.613.0 (0.77-6.93)
Total5299,831.727
  • NOTE: Hazards ratio adjusted for age and tumor-node-metastasis stage (I or II versus III or IV).

  • * Combination of SULT1E1 haplotypes reconstructed from SULT1E1 IVS1-447C < A, IVS4-1653T > C, and *959G > A.